Associated Papers
Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024.
Fornaguera A et al.
Journal of Clinical Medicine, 2025
Cytochrome P450 17 (CYP17), CYP2C19*2, CYP2C19*3 Gene Polymorphisms and Gastrointestinal Cancer Risk in Rural Maharashtra: A Hospital based Case-Control Study.
Datkhile KD et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2025
Effect of CYP2C19 polymorphism on response to bortezomib-based therapy in multiple myeloma patients.
Goel L et al.
The American Journal of the Medical Sciences, 2024
The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
Gudur RA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2024
The Diversity of CYP2C19 Polymorphisms in the Thai Population: Implications for Precision Medicine.
Nakhonsri V et al.
The Application of Clinical Genetics, 2024
Cas12a-based one-pot SNP detection with high accuracy.
Zhang HX et al.
Cell Insight, 2023
Pharmacogenetics of P2Y12 receptor inhibitors.
Thomas CD et al.
Pharmacotherapy, 2023
Introduction of new alternative pipeline using multiplexed fast COLD‑PCR together with sequencing approach highlighting pharmacoeconomics by detection of CYP variants.
Nandar YM et al.
Biomedical Reports, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review.
Forgerini M et al.
The Pharmacogenomics Journal, 2021
Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
Chuwongwattana S et al.
Pharmacology Research & Perspectives, 2020
CYP2C19 Allele Frequencies in Over 2.2 Million Direct-to-Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System.
Ionova Y et al.
Clinical and Translational Science, 2020
Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
Skadrić I et al.
International Journal of Legal Medicine, 2020
Comparison between MassARRAY and pyrosequencing for CYP2C19 and ABCB1 gene variants of clopidogrel efficiency genotyping.
Liu J et al.
Molecular Membrane Biology, 2019
The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting.
Grinshtein YI et al.
Genetic Testing and Molecular Biomarkers, 2018
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.
Brown SA et al.
Journal of Personalized Medicine, 2018
Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.
Guevara N et al.
Pharmaceuticals (basel, Switzerland), 2017
Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia.
Alhazzani AA et al.
Neurosciences (riyadh, Saudi Arabia), 2017
Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.
Sychev DA et al.
Pharmacogenomics and Personalized Medicine, 2017
The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
Uppugunduri CRS et al.
Frontiers in Pharmacology, 2017
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
Chuwongwattana S et al.
Drug Metabolism and Pharmacokinetics, 2016
Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.
Khalil BM et al.
Clinical and Translational Science, 2016
Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.
Abdelhedi R et al.
Journal of Genetics, 2015
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Wang XQ et al.
Gene, 2015
CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database.
Dai DP et al.
The Pharmacogenomics Journal, 2014
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2013
CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.
Musumba CO et al.
Clinical Pharmacology and Therapeutics, 2013
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors.
Sukasem C et al.
Pharmacogenomics and Personalized Medicine, 2013
Clinical pharmacogenomics of warfarin and clopidogrel.
Shin J
Journal of Pharmacy Practice, 2012
Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.
Seredina TA et al.
Bmc Medical Genetics, 2012
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves.
Lee KE et al.
Therapeutic Drug Monitoring, 2012
Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T et al.
Thrombosis Research, 2011
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Lakhan R et al.
The Indian Journal of Medical Research, 2011
Genetic determinants of on-clopidogrel high platelet reactivity.
Campo G et al.
Platelets, 2011
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA et al.
Basic & Clinical Pharmacology & Toxicology, 2010
Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.
Lee SJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2009
Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI et al.
European Journal of Clinical Pharmacology, 2009
Genetic determinants of response to clopidogrel and cardiovascular events.
Simon T et al.
The New England Journal of Medicine, 2009
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Zandvliet AS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2007
Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips.
Nakamoto K et al.
Pharmacogenetics and Genomics, 2007
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 2006
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
Takada K et al.
Arthritis and Rheumatism, 2004
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.
Goldstein JA
British Journal of Clinical Pharmacology, 2001
The Human Cytochrome P450 Allele Nomenclature Committee Web Site : Submission Criteria, Procedures, and Objectives.
Sim SC et al.
Methods in Molecular Biology (clifton, N.j.), 0